RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

NewsGuard 100/100 Score

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that over 2,000 patients with over 3000 fractures have been treated globally with the RF Kyphoplasty procedure using the StabiliT® Vertebral Augmentation System.

“We believe DFine’s technology is truly unique, increasing the potential for improved safety and patient outcomes by providing physicians unparalleled control in the treatment of vertebral compression fractures.”

“We are pleased to have reached this important milestone as we continue to build our distribution channel and expand commercialization efforts globally. It is particularly gratifying to hear the positive comments from spine specialists performing RF Kyphoplasty and most importantly the patients who have benefited from our products,” said Kevin Mosher, Chief Executive Officer of DFine Inc. “We believe DFine’s technology is truly unique, increasing the potential for improved safety and patient outcomes by providing physicians unparalleled control in the treatment of vertebral compression fractures.” With several pipeline products set for release later this year, DFine is poised to become the technology leader in the treatment of vertebral compression fractures increasing market presence and the availability of this minimally invasive treatment to spine specialists and patients around the world.

Source:

DFine, Inc.,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech